|
FDA Committee: Is Novel Anti-IL-5 Safe in Asthma?
MedPage Today In those two studies, with patients receiving reslizumab or placebo in addition to standard-of-care treatment, the asthma exacerbation frequency was decreased by at least half, with rate ratios of 0.50 (95% CI 0.37-0.67) and 0.41 (95% CI 0.28-0.59, P<0 … |
View full post on asthma – Google News